Status:
COMPLETED
Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists
Lead Sponsor:
Hospital for Special Surgery, New York
Conditions:
Gastric Ultrasound
Glucagon-like Peptide 1
Eligibility:
All Genders
18-99 years
Brief Summary
The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who take g...
Detailed Description
Glucagon-like peptide 1 (GLP-1) agonists have existed since 2005, however the newer once-weekly injectable medications particularly semaglutide, and tirzepatide have exploded in popularity due to thei...
Eligibility Criteria
Inclusion
- GLP 1 patient group: any patient on GLP1 agonists that are dosed once per week (semaglutide, dulaglutide, tirzepatide), for all indications.
- Control group (No GLP 1 patients): any patient not on GLP1 agonists that are dosed once per week, for all indications.
Exclusion
- patient refusal to participate
- patients with gastric bypass or any other gastric surgery
- large hiatal hernia
- patients with large ascites
- patients on peritoneal dialysis
- emergency surgery
- pre-existing diagnosis of gastroparesis
Key Trial Info
Start Date :
August 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2025
Estimated Enrollment :
354 Patients enrolled
Trial Details
Trial ID
NCT06003985
Start Date
August 29 2023
End Date
February 1 2025
Last Update
November 26 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
George Washington University Hospital
Washington D.C., District of Columbia, United States, 20037
2
Mayo Clinic
Jacksonville, Florida, United States, 32224
3
Albany Medical Center
Albany, New York, United States, 12208
4
Hospital for Special Surgery
New York, New York, United States, 10021